Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CNTA | Ordinary Shares | Award | $0 | +77.2K | +8.54% | $0.00 | 981K | Feb 1, 2023 | Direct | F1, F2 |
holding | CNTA | Ordinary Shares | 27.5K | Feb 1, 2023 | See footnote | F1, F3 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CNTA | Share Option (right to buy) | Award | $0 | +115K | $0.00 | 115K | Feb 1, 2023 | Ordinary Shares | 115K | $3.85 | Direct | F1, F4 |
Id | Content |
---|---|
F1 | The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
F2 | The shares reported in this transaction represent Restricted Share Units ("RSUs") issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one Ordinary Share of the Issuer. The RSUs shall vest and be settled in four equal annual installments with the first such annual vesting being on February 1, 2024. |
F3 | Held by RxCelerate Limited ("RxCelerate"). The Reporting Person is a member of the board of directors of RxCelerate. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by RxCelerate, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose. |
F4 | 1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2023. |